SK18852001A3 - Použitie látok potláčajúcich LTBR-sprostredkovanú aktiváciu - Google Patents
Použitie látok potláčajúcich LTBR-sprostredkovanú aktiváciu Download PDFInfo
- Publication number
- SK18852001A3 SK18852001A3 SK1885-2001A SK18852001A SK18852001A3 SK 18852001 A3 SK18852001 A3 SK 18852001A3 SK 18852001 A SK18852001 A SK 18852001A SK 18852001 A3 SK18852001 A3 SK 18852001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- ltbr
- mediated activation
- use according
- tumor
- activation
- Prior art date
Links
- 230000004913 activation Effects 0.000 title claims abstract description 13
- 230000001404 mediated effect Effects 0.000 title claims abstract description 5
- 101100153533 Mus musculus Ltbr gene Proteins 0.000 title 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims abstract description 27
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims abstract description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000004614 tumor growth Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 101150119053 LTBR gene Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001173 tumoral effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 description 14
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 5
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000012771 intravital microscopy Methods 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 108010010804 beta2 Heterotrimer Lymphotoxin alpha1 Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Marine Sciences & Fisheries (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1999129488 DE19929488A1 (de) | 1999-06-28 | 1999-06-28 | Verfahren zur Verhinderung von Tumorwachstum |
| DE2000104447 DE10004447A1 (de) | 2000-02-03 | 2000-02-03 | Verfahren zur Verhinderung von Tumorwachstum |
| PCT/EP2000/005738 WO2001000228A1 (de) | 1999-06-28 | 2000-06-21 | Verfahren zur verhinderung von tumorwachstum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK18852001A3 true SK18852001A3 (sk) | 2002-12-03 |
Family
ID=26004148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1885-2001A SK18852001A3 (sk) | 1999-06-28 | 2000-06-21 | Použitie látok potláčajúcich LTBR-sprostredkovanú aktiváciu |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1189626B1 (no) |
| JP (1) | JP3822822B2 (no) |
| KR (1) | KR20020016852A (no) |
| CN (1) | CN1359297A (no) |
| AT (1) | ATE410180T1 (no) |
| AU (1) | AU5406000A (no) |
| BG (1) | BG106246A (no) |
| BR (1) | BR0012006A (no) |
| CA (1) | CA2376920A1 (no) |
| DE (1) | DE50015391D1 (no) |
| ES (1) | ES2313893T3 (no) |
| HK (1) | HK1047045A1 (no) |
| HU (1) | HUP0201804A2 (no) |
| IL (1) | IL147180A0 (no) |
| MX (1) | MXPA01013367A (no) |
| NO (1) | NO20016380D0 (no) |
| PL (1) | PL353057A1 (no) |
| SK (1) | SK18852001A3 (no) |
| TR (1) | TR200103841T2 (no) |
| WO (1) | WO2001000228A1 (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL134994A0 (en) | 2000-03-09 | 2001-05-20 | Yeda Res & Dev | Coupled two way clustering analysis of data |
| KR20050090420A (ko) | 2002-12-26 | 2005-09-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 메타스틴 유도체 및 이의 용도 |
| AR049938A1 (es) | 2004-06-25 | 2006-09-13 | Takeda Pharmaceutical | Derivados de metastina y utilizacion de los mismos |
| EP1942936A2 (en) * | 2005-10-04 | 2008-07-16 | The Johns Hopkins University | Compositions and methods for treating inflammation |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
| JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
| US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| DK0954333T3 (da) * | 1996-10-25 | 2006-10-23 | Biogen Idec Inc | Oplöselige lymfotoksin-beta-receptorer, anti-lymfotoksinreceptor-antistoffer og anti-lymfotoksin-ligandantistoffer som terapeutiske midler til behandling af immunologiske sygdomme |
| HU226044B1 (en) * | 1998-01-30 | 2008-03-28 | Univ New York | Use of inhibitors of the lymhotoxin (lt) pathway to prepare pharmaceutical compositions for treatment of follicular lymphomas |
-
2000
- 2000-06-21 IL IL14718000A patent/IL147180A0/xx unknown
- 2000-06-21 AT AT00938807T patent/ATE410180T1/de not_active IP Right Cessation
- 2000-06-21 JP JP2001505936A patent/JP3822822B2/ja not_active Expired - Lifetime
- 2000-06-21 CA CA002376920A patent/CA2376920A1/en not_active Abandoned
- 2000-06-21 EP EP00938807A patent/EP1189626B1/de not_active Expired - Lifetime
- 2000-06-21 BR BR0012006-5A patent/BR0012006A/pt not_active IP Right Cessation
- 2000-06-21 SK SK1885-2001A patent/SK18852001A3/sk unknown
- 2000-06-21 HU HU0201804A patent/HUP0201804A2/hu unknown
- 2000-06-21 CN CN00809675A patent/CN1359297A/zh active Pending
- 2000-06-21 PL PL00353057A patent/PL353057A1/xx unknown
- 2000-06-21 AU AU54060/00A patent/AU5406000A/en not_active Abandoned
- 2000-06-21 WO PCT/EP2000/005738 patent/WO2001000228A1/de not_active Application Discontinuation
- 2000-06-21 MX MXPA01013367A patent/MXPA01013367A/es not_active Application Discontinuation
- 2000-06-21 KR KR1020017016689A patent/KR20020016852A/ko not_active Application Discontinuation
- 2000-06-21 DE DE50015391T patent/DE50015391D1/de not_active Expired - Fee Related
- 2000-06-21 TR TR2001/03841T patent/TR200103841T2/xx unknown
- 2000-06-21 ES ES00938807T patent/ES2313893T3/es not_active Expired - Lifetime
-
2001
- 2001-12-19 BG BG106246A patent/BG106246A/xx active Pending
- 2001-12-27 NO NO20016380A patent/NO20016380D0/no not_active Application Discontinuation
-
2002
- 2002-11-29 HK HK02108674.4A patent/HK1047045A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1047045A1 (zh) | 2003-02-07 |
| JP3822822B2 (ja) | 2006-09-20 |
| DE50015391D1 (de) | 2008-11-20 |
| CA2376920A1 (en) | 2001-01-04 |
| WO2001000228A1 (de) | 2001-01-04 |
| KR20020016852A (ko) | 2002-03-06 |
| JP2003503359A (ja) | 2003-01-28 |
| CN1359297A (zh) | 2002-07-17 |
| TR200103841T2 (tr) | 2002-06-21 |
| EP1189626B1 (de) | 2008-10-08 |
| NO20016380L (no) | 2001-12-27 |
| IL147180A0 (en) | 2002-08-14 |
| ES2313893T3 (es) | 2009-03-16 |
| BG106246A (en) | 2002-10-31 |
| MXPA01013367A (es) | 2002-07-02 |
| NO20016380D0 (no) | 2001-12-27 |
| EP1189626A1 (de) | 2002-03-27 |
| HUP0201804A2 (en) | 2002-09-28 |
| PL353057A1 (en) | 2003-10-06 |
| ATE410180T1 (de) | 2008-10-15 |
| AU5406000A (en) | 2001-01-31 |
| BR0012006A (pt) | 2002-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zemel et al. | A-type KV channels in dorsal root ganglion neurons: diversity, function, and dysfunction | |
| Kosai et al. | Hepatocyte growth factor prevents endotoxin‐induced lethal hepatic failure in mice | |
| Tanaka et al. | Downregulation of Fas ligand by shedding | |
| Bourinet et al. | Silencing of the Cav3. 2 T‐type calcium channel gene in sensory neurons demonstrates its major role in nociception | |
| Schulla et al. | Impaired insulin secretion and glucose tolerance in β cell‐selective CaV1. 2 Ca2+ channel null mice | |
| US9399668B2 (en) | Nucleic acids encoding rage fusion proteins | |
| US7429379B2 (en) | TNF receptor action modulation | |
| Dufour et al. | The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNFα-and FasL-induced apoptosis by interacting with caspase-8 | |
| US20030138884A1 (en) | APRIL- a novel protein with growth effects | |
| Zhang et al. | CD58 Immunobiology at a Glance | |
| Quattrocchi et al. | Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis | |
| JPH07145068A (ja) | 溶解型ｔｎｆ受容体のマルチマー、その製造方法、およびそれを含有する医薬組成物 | |
| US10724014B2 (en) | Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders | |
| CA3064556A1 (en) | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies | |
| WO2016139668A2 (en) | Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases | |
| O'Dea et al. | Lung-marginated monocytes modulate pulmonary microvascular injury during early endotoxemia | |
| SK18852001A3 (sk) | Použitie látok potláčajúcich LTBR-sprostredkovanú aktiváciu | |
| Mountz et al. | Apoptosis and rheumatoid arthritis: past, present, and future directions | |
| Cappello et al. | Death receptor ligands in tumors | |
| CA2507373A1 (en) | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases | |
| Ding et al. | Regulation of tumor necrosis factor receptors on phagocytes | |
| Xia et al. | Shedding of TNFR1 in regenerative liver can be induced with TNF α and PMA | |
| WO1999014325A1 (fr) | NOUVEAU DERIVE DU LIGAND Fas | |
| Linkermann et al. | The Fas ligand as a cell death factor and signal transducer | |
| US6156729A (en) | Leukemia inhibitory factor for use in modulating inflammation and pain |